Please assess the completion status of the following clinical trial:

Trial Title: Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. histologically proven uterine cervical cancer~2. squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix~3. one of the followings, 1)primary stage Ⅳb cervical cancer, 2)the first relapse or persistent cervical cancer after curative first line treatments, 3)the second relapse or persistent cervical cancer after curative second line treatments including radiation, systemic chemotherapy, hormonal therapy, or vaccination therapy for the first relapse~4. Patients may have been previously treated with less than 50 Gy of palliative radiation therapy~5. Patients have received no prior treatment or a certain interval must have elapsed from the last administration of previous treatments including palliative radiation therapy~6. one of the followings, 1)There is at least one metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN, 2)There is no metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN and some of the lesions have been irradiated, 3)All lesions are localized inside the pelvic cavity, and some of them have been irradiated~7. no prior surgical therapy for metastatic lesions of the lung or inside the pelvic cavity~8. no bilateral hydronephrosis~9. no prior chemotherapy including more than two platinum-containing regimens~10. no prior chemotherapy including taxane~11. age: 20 to75 years~12. PS: 0-2~13. ANC ≧1,500 /mm3, Plt≧10.0×104/mm3, T-bil≦1.5 mg/dl, GOT（AST）≦100IU/l, sCre ≦1.2 mg/dl, Ccr≧50ml/min in using the Cockcroft-Gault equation, and normal ECG~14. written informed consent~Exclusion Criteria:~1. patients who have some neurologically functional disorder~2. symptomatic CNS metastasis~3. hypersensitive to alcohol~4. active infection~5. HBs antigen positive~6. uncontrollable hypertension~7. history of myocardiac infarction within six months~8. unstable angina~9. uncontrollable diabetes~10. Patients with a concomitant or prior invasive malignancy (except intramucosal malignancy which are curable with local therapy) who have had any evidence of the disease within the last 5 years~11. women during pregnancy or breast-feeding~12. patients with psychiatric illness~13. patients who have been treated with the systemic steroids medication

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Drug: chemotherapy: Paclitaxel/Cisplatin
- 2 (Type: EXPERIMENTAL): Drug: chemotherapy: Paclitaxel/Carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).